[
  {
    "text": "<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",
    "position": 0,
    "name": "Application Received",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2021",
          "fs": "Nov 2021",
          "change": null
        },
        "Event_Description": {
          "s": "Application received",
          "fs": "Application received",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVR2A3"
          },
          "Id": "a0POZ00000CdCVR2A3",
          "Event_Date__c": "2021-11-15",
          "Event_Description__c": "Application received",
          "Stage__c": "Application Received",
          "Formatted_Date__c": "Nov 2021",
          "Status_History__c": "a132P000000DLT1QAO"
        },
        "change": null
      }
    ],
    "dateString": "Nov 2021",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/\" rel=\"nofollow\">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/\" rel=\"nofollow\">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>\n<p style=\"height: 15px\">&nbsp;</p>\n<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>\n<p style=\"height: 20px\">&nbsp;</p>\n<p><a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/\" rel=\"nofollow\">PTAC</a>  and <a class=\"external-link\" href=\"https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//\" rel=\"nofollow\">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",
    "position": 1,
    "name": "Seeking Clinical Advice",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Mar 2023",
          "fs": "Mar 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice required",
          "fs": "Clinical advice required",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVS2A3"
          },
          "Id": "a0POZ00000CdCVS2A3",
          "Event_Date__c": "2023-03-13",
          "Event_Description__c": "Clinical advice required",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "Mar 2023",
          "Status_History__c": "a132P000000EDTkQAO"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "May 2023",
          "fs": "May 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023",
          "fs": "Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVT2A3"
          },
          "Id": "a0POZ00000CdCVT2A3",
          "Event_Date__c": "2023-05-23",
          "Event_Description__c": "Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023",
          "Stage__c": "Seeking Clinical Advice",
          "Formatted_Date__c": "May 2023",
          "Status_History__c": "a132P000000EE00QAG"
        },
        "change": null
      },
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee <strong>recommended</strong> access to adalimumab be amended to include the treatment of genital or flexural psoriasis with a<strong> high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria (additions in <strong>bold</strong>):</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Initial application \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has experienced intolerable side effects; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; </span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Or </span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">All of the following:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">2.1.3.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, with a Dermatology Life Quality Index (DLQI) score greater than 10; and </strong></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has tried, but received insufficient therapeutic effect from, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.</span></p><p><span style=\"font-size: 9pt;\">\u00a0</span></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Renewal \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had &quot;whole body&quot; severe chronic plaque psoriasis at the start of treatment; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; or</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both; </span></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient had severe chronic localised genital or flexural plaque psoriasis; and</strong></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Either</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab</strong></p><p><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee noted</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with genital or flexural psoriasis</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The sensitive psychosocial aspects of genital and flexural psoriasis.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The lack of current treatments, and the unsuitability of topical creams, and cultural considerations of topical application.\u00a0\u00a0</p><p><br></p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee <strong>recommended</strong> access to adalimumab be amended to include the treatment of genital or flexural psoriasis with a<strong> high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria (additions in <strong>bold</strong>):</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Initial application \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has experienced intolerable side effects; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; </span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Or </span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">All of the following:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">2.1.3.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, with a Dermatology Life Quality Index (DLQI) score greater than 10; and </strong></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has tried, but received insufficient therapeutic effect from, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.</span></p><p><span style=\"font-size: 9pt;\">\u00a0</span></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Renewal \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had &quot;whole body&quot; severe chronic plaque psoriasis at the start of treatment; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; or</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both; </span></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient had severe chronic localised genital or flexural plaque psoriasis; and</strong></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Either</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab</strong></p><p><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee noted</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with genital or flexural psoriasis</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The sensitive psychosocial aspects of genital and flexural psoriasis.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The lack of current treatments, and the unsuitability of topical creams, and cultural considerations of topical application.\u00a0\u00a0</p><p><br></p>",
          "change": null
        },
        "Published_Discussion": {
          "s": "<p><em>M\u0101ori impact </em></p><p><em>1.1.</em><em style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</em>The<em> </em>Committee discussed the impact of funding adalimumab for the treatment of genital or flexural psoriasis on Hauora Arotahi - M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that reported M\u0101ori and Pacific peoples were overrepresented in the numbers treated for psoriasis in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted no treatments have previously considered for this specific type of psoriasis, but other pharmaceuticals have been considered, and funded, for the broader indication of chronic plaque psoriasis. </p><p><br></p><p><em>Health need</em></p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted flexural psoriasis, also known as inverse or intertriginous psoriasis, is characterised by thickened areas of skin localised to the skin folds and genitals. Common sites of flexural psoriasis are the armpits, groin, and natal cleft. </p><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the pathogenesis does not differ from plaque psoriasis. The Committee noted that the skin appears macerated and can often become infected with <em>Candida</em>. The condition may be present exclusively, or in combination with classical plaque psoriasis lesions in other body areas (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997231/#:~:text=Inverse%20psoriasis%20(IP)%2C%20also,%2C%20anogenital%2C%20and%20inframammary%20ones.\" target=\"_blank\">Micali et al, Clin Cosmet Investig Dermatol. 2019; 12: 953\u2013959</a>).</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that those with genital or flexural psoriasis had a high health need due to the condition being very distressing, and due to the location of the symptoms also causing high levels of embarrassment. </p><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 2% of the population are affected by psoriasis, with a recent study reporting an occurrence of 1.58% (0.5-5.73%) in Australasia (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254147/\" target=\"_blank\">Parisis et al, BMJ. 2020; 369: 1590</a>). Of this population, involvement of the genitals is relatively common occurring in 29-40% of all individuals, with the prevalence broadly increasing with the severity of the psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/32434510/\" target=\"_blank\">Egeberg et al, BMC Dermatol. 2020;20:3</a>; <a href=\"https://pubmed.ncbi.nlm.nih.gov/31313079/\" target=\"_blank\">Kelly et al, Am J Clin Dermatol. 2019; 20:639-646</a>). Psoriasis that is largely confined to the genitals, occurs in approximately 2-5% of individuals with psoriasis, although this may be under diagnosed, with approximately half of those with genital lesions not discussing their symptoms with their physician (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al, Psoriasis (Auckl). 2018; 8: 41\u201347</a>). It has been estimated that flexural psoriasis affects between 6.8-36% of those with psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17907013/\" target=\"_blank\">Van de Kerkhof et al, J Dermatolog Treat. 2007;18:351-60</a>). </p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered this form of psoriasis was under reported by those with the condition. </p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 72% of individuals with genital psoriasis feel uncomfortable about dating and 60% report that this disease has prevented them from pursuing an intimate relationship (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al,\u00a02018</a>).</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted psoriasis is detrimental to the quality of life of the person who is affected. It is often linked with social stigmatisation, loss of self-confidence, pain, discomfort, physical disability, and psychological distress. Many of those with psoriasis report moderate to extreme feelings of anxiety, anger, and depression and higher frequency of suicidal ideation (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134161/\" target=\"_blank\">Sarker et al, Indian Dermatol Online J. 2016; 7: 481\u2013488</a>).</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted those with genital psoriasis also report chronic intense itching, burning skin and pain, with a worsening of symptoms following intercourse (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, J Am Acad Dermatol. 2015;72:978-83</a>). Individuals with genital psoriasis had more impairment in quality of life and sexual health as determined by the Dermatology Life Quality Index (P &lt; .0001), the Centre for Epidemiological Studies-Depression Scale (P = .01), and the Relationship and Sexuality Scale (P &lt; .0001) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, 2015</a>).</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that most individuals are treated with topical corticosteroids. However, these have adverse effects including skin atrophy, and are usually administered sparingly for short periods of time. The Committee also noted that thin skin and constant occlusion of this environment cause topical medications to have increased penetration in the groin area, increasing the risk of systemic side effects (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261118/\" target=\"_blank\">Beck et al, Dermatol Ther (Heidelb). 2018; 8: 509\u2013525</a>). The Committee noted individuals progress to systemic treatments including acitretin or methotrexate, and occasionally cyclosporin however these are not commonly used. </p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that a review of people treated in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) had found that of 511 people treated for psoriasis, 26.42% of individuals were of M\u0101ori and Pacific ethnicity. As a comparison, the general ADHB population was comprised of 19.1% M\u0101ori and Pacific peoples and 52% New Zealand Europeans at the time (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb.2014</a>).</p><p><br></p><p><em>Health benefit</em></p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab binds to tumour necrosis factor (TNF) and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Increased levels of TNF are found in psoriasis plaques, which contribute to the inflammatory response, to the proliferation and decreased maturation of keratinocytes and to the associated vascular damages that are characteristic of the disease.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted health benefit evidence for adalimumab for the treatment of plaque psoriasis was reviewed by PTAC in <a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf\" target=\"_blank\">2008</a>, which recommended it be given a medium priority for funding, whilst noting other biologics may be acceptable. </p><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://pubmed.ncbi.nlm.nih.gov/31595647/\" target=\"_blank\">Burlando et al, Dermatol Ther. 2020;33:e13110</a> study that examined which biologic therapy is more effective on genital psoriasis in 74 women, of which 34% had genital psoriasis. Of 10 that received anti-TNF therapies (8 adalimumab, 1 etanercept, 1 certolizumab) four individuals reached PASI 90. Improved responses were also reported in those that received secukinumab, ixekizumab and ustekinumab. </p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://s3-eu-west-1.amazonaws.com/thejournalhub/10.15570/v10162-012-0049-5/v10162-012-0049-5.pdf\" target=\"_blank\">Je\u0161e et al, Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:21-3</a> study of one male with inverse psoriasis. At 6 months follow up after adalimumab treatment, psoriatic lesions had resolved, and quality of life measures (Health Assessment Questionnaire: Patient-Reported Outcomes Measurement Information and Dermatology Life Quality Index) were significantly improved. </p><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered other biologic treatments including etanercept, infliximab, ustekinumab and guselkumab would be beneficial to those who have flexural or genital psoriasis. The Committee considered that treatment of genital and flexural psoriasis should be similar to those who have chronic plaque psoriasis, or who have psoriasis located on the hands, feet or face.</p><p><br></p><p><em>Suitability</em></p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab is a prefilled syringe or pen that enables individuals to self-administer their treatment, if appropriate, with medical follow-up as necessary, after proper training in subcutaneous injection technique.</p><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted other treatments require daily oral or topical administration. In addition, these topical administrations can be painful or uncomfortable when administered to the skin.</p><p>1.20.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that for some individuals, topical administration to the skin, in areas affected by genital or flexural psoriasis, may not be suitable for religious or cultural reasons. </p><p><br></p><p><em>Cost and savings</em></p><p>1.21.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered many individuals would already be receiving biologic treatment for psoriasis in other regions of the body, and it was common for people with this subtype of psoriasis to present with whole-body disease. The Committee considered that less than 10% of those with psoriasis would only present with flexural or genital psoriasis.\u00a0</p><p>1.22.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered a small percentage with flexural psoriasis or genital psoriasis may not reach the current Special Authority criteria threshold PASI score (greater than 10) for biologic treatment. The Committee considered that PASI scores did not accurately reflect the disease severity of those with flexural or genital psoriasis, as the PASI typically reflected disease activity for those with whole body psoriasis. The Committee considered that whilst DLQI would be most reflective of disease severity, the change in PASI scores for whole body psoriasis could be used to model an estimate of benefit for these groups, however DLQI would be a better measure of treatment success.</p><p>1.23.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered it was likely that the health gains for this subpopulation would be similar to those treated with biologics for whole body psoriasis. However, the Committee considered that it was uncertain whether the quality-of-life impacts associated with a PASI 75 could be used as a proxy for the quality-of-life improvement associated with a DLQI improvement for this disease subtype.</p><p>1.24.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered some individuals may still prefer to use topical products. </p><p>1.25.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that similar health benefit gains would be observed in those with genital or flexural psoriasis treated with adalimumab as those with whole body chronic severe plaque psoriasis or where it is located on the hands, feet, and face. </p><p>1.26.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered the frequency of dosing would likely be similar for this group as for those with chronic plaque psoriasis or those with psoriasis of the hands, feet, and face.</p><p><br></p><p><em>Funding Criteria</em></p><p>1.27.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted dermatology life quality index (DLQI) score is more appropriate when assessing health benefit for genital or flexural psoriasis. </p><p>1.28.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that the if the adalimumab Special Authority criteria were to be amended, they should align with the Special Authorities for other biologic treatments for plaque psoriasis, allowing subsequent treatment of genital or flexural psoriasis with those agents as well.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"color: black;\">The Advisory Committee considered that the table below summarises its interpretation of the </span>most<span style=\"color: black;\"> appropriate PICO (population, intervention, comparator, outcomes) information for adalimumab if it were to be funded in New Zealand for flexural or genital psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=\"color: black;\">\ufeff</span><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000CdCVW&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000cvwX\" alt=\"image.png\"></img></p>",
          "fs": "<p><em>M\u0101ori impact </em></p><p><em>1.1.</em><em style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</em>The<em> </em>Committee discussed the impact of funding adalimumab for the treatment of genital or flexural psoriasis on Hauora Arotahi - M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that reported M\u0101ori and Pacific peoples were overrepresented in the numbers treated for psoriasis in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted no treatments have previously considered for this specific type of psoriasis, but other pharmaceuticals have been considered, and funded, for the broader indication of chronic plaque psoriasis. </p><p><br></p><p><em>Health need</em></p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted flexural psoriasis, also known as inverse or intertriginous psoriasis, is characterised by thickened areas of skin localised to the skin folds and genitals. Common sites of flexural psoriasis are the armpits, groin, and natal cleft. </p><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the pathogenesis does not differ from plaque psoriasis. The Committee noted that the skin appears macerated and can often become infected with <em>Candida</em>. The condition may be present exclusively, or in combination with classical plaque psoriasis lesions in other body areas (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997231/#:~:text=Inverse%20psoriasis%20(IP)%2C%20also,%2C%20anogenital%2C%20and%20inframammary%20ones.\" target=\"_blank\">Micali et al, Clin Cosmet Investig Dermatol. 2019; 12: 953\u2013959</a>).</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that those with genital or flexural psoriasis had a high health need due to the condition being very distressing, and due to the location of the symptoms also causing high levels of embarrassment. </p><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 2% of the population are affected by psoriasis, with a recent study reporting an occurrence of 1.58% (0.5-5.73%) in Australasia (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254147/\" target=\"_blank\">Parisis et al, BMJ. 2020; 369: 1590</a>). Of this population, involvement of the genitals is relatively common occurring in 29-40% of all individuals, with the prevalence broadly increasing with the severity of the psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/32434510/\" target=\"_blank\">Egeberg et al, BMC Dermatol. 2020;20:3</a>; <a href=\"https://pubmed.ncbi.nlm.nih.gov/31313079/\" target=\"_blank\">Kelly et al, Am J Clin Dermatol. 2019; 20:639-646</a>). Psoriasis that is largely confined to the genitals, occurs in approximately 2-5% of individuals with psoriasis, although this may be under diagnosed, with approximately half of those with genital lesions not discussing their symptoms with their physician (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al, Psoriasis (Auckl). 2018; 8: 41\u201347</a>). It has been estimated that flexural psoriasis affects between 6.8-36% of those with psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17907013/\" target=\"_blank\">Van de Kerkhof et al, J Dermatolog Treat. 2007;18:351-60</a>). </p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered this form of psoriasis was under reported by those with the condition. </p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 72% of individuals with genital psoriasis feel uncomfortable about dating and 60% report that this disease has prevented them from pursuing an intimate relationship (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al,\u00a02018</a>).</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted psoriasis is detrimental to the quality of life of the person who is affected. It is often linked with social stigmatisation, loss of self-confidence, pain, discomfort, physical disability, and psychological distress. Many of those with psoriasis report moderate to extreme feelings of anxiety, anger, and depression and higher frequency of suicidal ideation (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134161/\" target=\"_blank\">Sarker et al, Indian Dermatol Online J. 2016; 7: 481\u2013488</a>).</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted those with genital psoriasis also report chronic intense itching, burning skin and pain, with a worsening of symptoms following intercourse (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, J Am Acad Dermatol. 2015;72:978-83</a>). Individuals with genital psoriasis had more impairment in quality of life and sexual health as determined by the Dermatology Life Quality Index (P &lt; .0001), the Centre for Epidemiological Studies-Depression Scale (P = .01), and the Relationship and Sexuality Scale (P &lt; .0001) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, 2015</a>).</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that most individuals are treated with topical corticosteroids. However, these have adverse effects including skin atrophy, and are usually administered sparingly for short periods of time. The Committee also noted that thin skin and constant occlusion of this environment cause topical medications to have increased penetration in the groin area, increasing the risk of systemic side effects (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261118/\" target=\"_blank\">Beck et al, Dermatol Ther (Heidelb). 2018; 8: 509\u2013525</a>). The Committee noted individuals progress to systemic treatments including acitretin or methotrexate, and occasionally cyclosporin however these are not commonly used. </p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that a review of people treated in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) had found that of 511 people treated for psoriasis, 26.42% of individuals were of M\u0101ori and Pacific ethnicity. As a comparison, the general ADHB population was comprised of 19.1% M\u0101ori and Pacific peoples and 52% New Zealand Europeans at the time (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb.2014</a>).</p><p><br></p><p><em>Health benefit</em></p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab binds to tumour necrosis factor (TNF) and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Increased levels of TNF are found in psoriasis plaques, which contribute to the inflammatory response, to the proliferation and decreased maturation of keratinocytes and to the associated vascular damages that are characteristic of the disease.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted health benefit evidence for adalimumab for the treatment of plaque psoriasis was reviewed by PTAC in <a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf\" target=\"_blank\">2008</a>, which recommended it be given a medium priority for funding, whilst noting other biologics may be acceptable. </p><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://pubmed.ncbi.nlm.nih.gov/31595647/\" target=\"_blank\">Burlando et al, Dermatol Ther. 2020;33:e13110</a> study that examined which biologic therapy is more effective on genital psoriasis in 74 women, of which 34% had genital psoriasis. Of 10 that received anti-TNF therapies (8 adalimumab, 1 etanercept, 1 certolizumab) four individuals reached PASI 90. Improved responses were also reported in those that received secukinumab, ixekizumab and ustekinumab. </p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://s3-eu-west-1.amazonaws.com/thejournalhub/10.15570/v10162-012-0049-5/v10162-012-0049-5.pdf\" target=\"_blank\">Je\u0161e et al, Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:21-3</a> study of one male with inverse psoriasis. At 6 months follow up after adalimumab treatment, psoriatic lesions had resolved, and quality of life measures (Health Assessment Questionnaire: Patient-Reported Outcomes Measurement Information and Dermatology Life Quality Index) were significantly improved. </p><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered other biologic treatments including etanercept, infliximab, ustekinumab and guselkumab would be beneficial to those who have flexural or genital psoriasis. The Committee considered that treatment of genital and flexural psoriasis should be similar to those who have chronic plaque psoriasis, or who have psoriasis located on the hands, feet or face.</p><p><br></p><p><em>Suitability</em></p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab is a prefilled syringe or pen that enables individuals to self-administer their treatment, if appropriate, with medical follow-up as necessary, after proper training in subcutaneous injection technique.</p><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted other treatments require daily oral or topical administration. In addition, these topical administrations can be painful or uncomfortable when administered to the skin.</p><p>1.20.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that for some individuals, topical administration to the skin, in areas affected by genital or flexural psoriasis, may not be suitable for religious or cultural reasons. </p><p><br></p><p><em>Cost and savings</em></p><p>1.21.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered many individuals would already be receiving biologic treatment for psoriasis in other regions of the body, and it was common for people with this subtype of psoriasis to present with whole-body disease. The Committee considered that less than 10% of those with psoriasis would only present with flexural or genital psoriasis.\u00a0</p><p>1.22.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered a small percentage with flexural psoriasis or genital psoriasis may not reach the current Special Authority criteria threshold PASI score (greater than 10) for biologic treatment. The Committee considered that PASI scores did not accurately reflect the disease severity of those with flexural or genital psoriasis, as the PASI typically reflected disease activity for those with whole body psoriasis. The Committee considered that whilst DLQI would be most reflective of disease severity, the change in PASI scores for whole body psoriasis could be used to model an estimate of benefit for these groups, however DLQI would be a better measure of treatment success.</p><p>1.23.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered it was likely that the health gains for this subpopulation would be similar to those treated with biologics for whole body psoriasis. However, the Committee considered that it was uncertain whether the quality-of-life impacts associated with a PASI 75 could be used as a proxy for the quality-of-life improvement associated with a DLQI improvement for this disease subtype.</p><p>1.24.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered some individuals may still prefer to use topical products. </p><p>1.25.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that similar health benefit gains would be observed in those with genital or flexural psoriasis treated with adalimumab as those with whole body chronic severe plaque psoriasis or where it is located on the hands, feet, and face. </p><p>1.26.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered the frequency of dosing would likely be similar for this group as for those with chronic plaque psoriasis or those with psoriasis of the hands, feet, and face.</p><p><br></p><p><em>Funding Criteria</em></p><p>1.27.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted dermatology life quality index (DLQI) score is more appropriate when assessing health benefit for genital or flexural psoriasis. </p><p>1.28.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that the if the adalimumab Special Authority criteria were to be amended, they should align with the Special Authorities for other biologic treatments for plaque psoriasis, allowing subsequent treatment of genital or flexural psoriasis with those agents as well.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"color: black;\">The Advisory Committee considered that the table below summarises its interpretation of the </span>most<span style=\"color: black;\"> appropriate PICO (population, intervention, comparator, outcomes) information for adalimumab if it were to be funded in New Zealand for flexural or genital psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=\"color: black;\">\ufeff</span><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000CdCVW&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000cvwX\" alt=\"image.png\"></img></p>",
          "change": null
        },
        "Published_Application": {
          "s": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee reviewed the application for adalimumab for the treatment of flexural or genital psoriasis.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.</p>",
          "fs": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee reviewed the application for adalimumab for the treatment of flexural or genital psoriasis.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.</p>",
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": "High",
          "fs": "High",
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Nov 2023",
          "fs": "Nov 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.",
          "fs": "Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVW2A3"
          },
          "Id": "a0POZ00000CdCVW2A3",
          "Event_Date__c": "2023-11-29",
          "Event_Description__c": "Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.",
          "Stage__c": "Seeking Clinical Advice",
          "Outcome__c": "High",
          "Formatted_Date__c": "Nov 2023",
          "Published_Recommendation__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee <strong>recommended</strong> access to adalimumab be amended to include the treatment of genital or flexural psoriasis with a<strong> high priority</strong> within the context of dermatology treatments subject to the following Special Authority criteria (additions in <strong>bold</strong>):</p><p><br></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Initial application \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has experienced intolerable side effects; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has received insufficient benefit to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; </span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Or </span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">All of the following:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a PASI score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; or</span></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">2.1.3.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has severe chronic localised genital or flexural plaque psoriasis where the plaques or lesions have been present for at least 6 months from the time of initial diagnosis, with a Dermatology Life Quality Index (DLQI) score greater than 10; and </strong></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient has tried, but received insufficient therapeutic effect from, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, ciclosporin, or acitretin; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">A PASI assessment or DLQI assessment has been completed for at least the most recent prior treatment course but no longer than 1 month following cessation of each prior treatment course and is no more than 1 month old at the time of application.</span></p><p><span style=\"font-size: 9pt;\">\u00a0</span></p><p class=\"ql-indent-1\"><strong style=\"font-size: 9pt;\">Renewal \u2014 (Plaque psoriasis - severe chronic)</strong><span style=\"font-size: 9pt;\"> from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:</span></p><p class=\"ql-indent-1\"><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had &quot;whole body&quot; severe chronic plaque psoriasis at the start of treatment; and</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">1.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either:</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">1.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both:</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; or</span></p><p class=\"ql-indent-3\"><span style=\"font-size: 9pt;\">2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Either</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.1.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.2.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</span></p><p class=\"ql-indent-4\"><span style=\"font-size: 9pt;\">2.2.3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0</span><span style=\"font-size: 9pt;\">The patient has a DLQI improvement of 5 or more, when compared with the pre-treatment baseline value; or</span></p><p class=\"ql-indent-2\"><span style=\"font-size: 9pt;\">3.</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0</span><span style=\"font-size: 9pt;\">Both; </span></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient had severe chronic localised genital or flexural plaque psoriasis; and</strong></p><p class=\"ql-indent-3\"><strong style=\"font-size: 9pt;\">3.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Either</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.1.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">The patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value or</strong></p><p class=\"ql-indent-4\"><strong style=\"font-size: 9pt;\">3.2.2.</strong><strong style=\"font-size: 7pt;\">\u00a0\u00a0</strong><strong style=\"font-size: 9pt;\">Patient has a Dermatology Quality of Life Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing adalimumab</strong></p><p><br></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee noted</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The high health need of those with genital or flexural psoriasis</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The sensitive psychosocial aspects of genital and flexural psoriasis.</p><p class=\"ql-indent-1\"><span style=\"font-family: Symbol;\">\u00b7</span><span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The lack of current treatments, and the unsuitability of topical creams, and cultural considerations of topical application.\u00a0\u00a0</p><p><br></p>",
          "Published_Application__c": "<p>1.1.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee reviewed the application for adalimumab for the treatment of flexural or genital psoriasis.</p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Advisory Committee took into account, where applicable, Pharmac\u2019s relevant decision-making framework when considering this agenda item.</p>",
          "Published_Discussion__c": "<p><em>M\u0101ori impact </em></p><p><em>1.1.</em><em style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</em>The<em> </em>Committee discussed the impact of funding adalimumab for the treatment of genital or flexural psoriasis on Hauora Arotahi - M\u0101ori health areas of focus and M\u0101ori health outcomes. The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that reported M\u0101ori and Pacific peoples were overrepresented in the numbers treated for psoriasis in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p><br></p><p><em>Background</em></p><p>1.2.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted no treatments have previously considered for this specific type of psoriasis, but other pharmaceuticals have been considered, and funded, for the broader indication of chronic plaque psoriasis. </p><p><br></p><p><em>Health need</em></p><p>1.3.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted flexural psoriasis, also known as inverse or intertriginous psoriasis, is characterised by thickened areas of skin localised to the skin folds and genitals. Common sites of flexural psoriasis are the armpits, groin, and natal cleft. </p><p>1.4.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted the pathogenesis does not differ from plaque psoriasis. The Committee noted that the skin appears macerated and can often become infected with <em>Candida</em>. The condition may be present exclusively, or in combination with classical plaque psoriasis lesions in other body areas (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997231/#:~:text=Inverse%20psoriasis%20(IP)%2C%20also,%2C%20anogenital%2C%20and%20inframammary%20ones.\" target=\"_blank\">Micali et al, Clin Cosmet Investig Dermatol. 2019; 12: 953\u2013959</a>).</p><p>1.5.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted that those with genital or flexural psoriasis had a high health need due to the condition being very distressing, and due to the location of the symptoms also causing high levels of embarrassment. </p><p>1.6.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 2% of the population are affected by psoriasis, with a recent study reporting an occurrence of 1.58% (0.5-5.73%) in Australasia (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254147/\" target=\"_blank\">Parisis et al, BMJ. 2020; 369: 1590</a>). Of this population, involvement of the genitals is relatively common occurring in 29-40% of all individuals, with the prevalence broadly increasing with the severity of the psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/32434510/\" target=\"_blank\">Egeberg et al, BMC Dermatol. 2020;20:3</a>; <a href=\"https://pubmed.ncbi.nlm.nih.gov/31313079/\" target=\"_blank\">Kelly et al, Am J Clin Dermatol. 2019; 20:639-646</a>). Psoriasis that is largely confined to the genitals, occurs in approximately 2-5% of individuals with psoriasis, although this may be under diagnosed, with approximately half of those with genital lesions not discussing their symptoms with their physician (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al, Psoriasis (Auckl). 2018; 8: 41\u201347</a>). It has been estimated that flexural psoriasis affects between 6.8-36% of those with psoriasis (<a href=\"https://pubmed.ncbi.nlm.nih.gov/17907013/\" target=\"_blank\">Van de Kerkhof et al, J Dermatolog Treat. 2007;18:351-60</a>). </p><p>1.7.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee considered this form of psoriasis was under reported by those with the condition. </p><p>1.8.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted approximately 72% of individuals with genital psoriasis feel uncomfortable about dating and 60% report that this disease has prevented them from pursuing an intimate relationship (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118254/\" target=\"_blank\">Yang et al,\u00a02018</a>).</p><p>1.9.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0</span>The Committee noted psoriasis is detrimental to the quality of life of the person who is affected. It is often linked with social stigmatisation, loss of self-confidence, pain, discomfort, physical disability, and psychological distress. Many of those with psoriasis report moderate to extreme feelings of anxiety, anger, and depression and higher frequency of suicidal ideation (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134161/\" target=\"_blank\">Sarker et al, Indian Dermatol Online J. 2016; 7: 481\u2013488</a>).</p><p>1.10.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted those with genital psoriasis also report chronic intense itching, burning skin and pain, with a worsening of symptoms following intercourse (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, J Am Acad Dermatol. 2015;72:978-83</a>). Individuals with genital psoriasis had more impairment in quality of life and sexual health as determined by the Dermatology Life Quality Index (P &lt; .0001), the Centre for Epidemiological Studies-Depression Scale (P = .01), and the Relationship and Sexuality Scale (P &lt; .0001) (<a href=\"https://pubmed.ncbi.nlm.nih.gov/25824273/\" target=\"_blank\">Ryan et al, 2015</a>).</p><p>1.11.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that most individuals are treated with topical corticosteroids. However, these have adverse effects including skin atrophy, and are usually administered sparingly for short periods of time. The Committee also noted that thin skin and constant occlusion of this environment cause topical medications to have increased penetration in the groin area, increasing the risk of systemic side effects (<a href=\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261118/\" target=\"_blank\">Beck et al, Dermatol Ther (Heidelb). 2018; 8: 509\u2013525</a>). The Committee noted individuals progress to systemic treatments including acitretin or methotrexate, and occasionally cyclosporin however these are not commonly used. </p><p>1.12.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal which reported that a review of people treated in the Auckland District Health Board (ADHB) over the last 5 years (2009\u20132014) had found that of 511 people treated for psoriasis, 26.42% of individuals were of M\u0101ori and Pacific ethnicity. As a comparison, the general ADHB population was comprised of 19.1% M\u0101ori and Pacific peoples and 52% New Zealand Europeans at the time (<a href=\"https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective\" target=\"_blank\">Lee and Lamb.2014</a>).</p><p><br></p><p><em>Health benefit</em></p><p>1.13.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab binds to tumour necrosis factor (TNF) and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Increased levels of TNF are found in psoriasis plaques, which contribute to the inflammatory response, to the proliferation and decreased maturation of keratinocytes and to the associated vascular damages that are characteristic of the disease.</p><p>1.14.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted health benefit evidence for adalimumab for the treatment of plaque psoriasis was reviewed by PTAC in <a href=\"https://pharmac.govt.nz/assets/ptac-minutes-2008-07.pdf\" target=\"_blank\">2008</a>, which recommended it be given a medium priority for funding, whilst noting other biologics may be acceptable. </p><p>1.15.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://pubmed.ncbi.nlm.nih.gov/31595647/\" target=\"_blank\">Burlando et al, Dermatol Ther. 2020;33:e13110</a> study that examined which biologic therapy is more effective on genital psoriasis in 74 women, of which 34% had genital psoriasis. Of 10 that received anti-TNF therapies (8 adalimumab, 1 etanercept, 1 certolizumab) four individuals reached PASI 90. Improved responses were also reported in those that received secukinumab, ixekizumab and ustekinumab. </p><p>1.16.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted the <a href=\"https://s3-eu-west-1.amazonaws.com/thejournalhub/10.15570/v10162-012-0049-5/v10162-012-0049-5.pdf\" target=\"_blank\">Je\u0161e et al, Acta Dermatovenerol Alp Pannonica Adriat. 2014;23:21-3</a> study of one male with inverse psoriasis. At 6 months follow up after adalimumab treatment, psoriatic lesions had resolved, and quality of life measures (Health Assessment Questionnaire: Patient-Reported Outcomes Measurement Information and Dermatology Life Quality Index) were significantly improved. </p><p>1.17.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered other biologic treatments including etanercept, infliximab, ustekinumab and guselkumab would be beneficial to those who have flexural or genital psoriasis. The Committee considered that treatment of genital and flexural psoriasis should be similar to those who have chronic plaque psoriasis, or who have psoriasis located on the hands, feet or face.</p><p><br></p><p><em>Suitability</em></p><p>1.18.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted adalimumab is a prefilled syringe or pen that enables individuals to self-administer their treatment, if appropriate, with medical follow-up as necessary, after proper training in subcutaneous injection technique.</p><p>1.19.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted other treatments require daily oral or topical administration. In addition, these topical administrations can be painful or uncomfortable when administered to the skin.</p><p>1.20.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted that for some individuals, topical administration to the skin, in areas affected by genital or flexural psoriasis, may not be suitable for religious or cultural reasons. </p><p><br></p><p><em>Cost and savings</em></p><p>1.21.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered many individuals would already be receiving biologic treatment for psoriasis in other regions of the body, and it was common for people with this subtype of psoriasis to present with whole-body disease. The Committee considered that less than 10% of those with psoriasis would only present with flexural or genital psoriasis.\u00a0</p><p>1.22.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered a small percentage with flexural psoriasis or genital psoriasis may not reach the current Special Authority criteria threshold PASI score (greater than 10) for biologic treatment. The Committee considered that PASI scores did not accurately reflect the disease severity of those with flexural or genital psoriasis, as the PASI typically reflected disease activity for those with whole body psoriasis. The Committee considered that whilst DLQI would be most reflective of disease severity, the change in PASI scores for whole body psoriasis could be used to model an estimate of benefit for these groups, however DLQI would be a better measure of treatment success.</p><p>1.23.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered it was likely that the health gains for this subpopulation would be similar to those treated with biologics for whole body psoriasis. However, the Committee considered that it was uncertain whether the quality-of-life impacts associated with a PASI 75 could be used as a proxy for the quality-of-life improvement associated with a DLQI improvement for this disease subtype.</p><p>1.24.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered some individuals may still prefer to use topical products. </p><p>1.25.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that similar health benefit gains would be observed in those with genital or flexural psoriasis treated with adalimumab as those with whole body chronic severe plaque psoriasis or where it is located on the hands, feet, and face. </p><p>1.26.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered the frequency of dosing would likely be similar for this group as for those with chronic plaque psoriasis or those with psoriasis of the hands, feet, and face.</p><p><br></p><p><em>Funding Criteria</em></p><p>1.27.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee noted dermatology life quality index (DLQI) score is more appropriate when assessing health benefit for genital or flexural psoriasis. </p><p>1.28.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span>The Committee considered that the if the adalimumab Special Authority criteria were to be amended, they should align with the Special Authorities for other biologic treatments for plaque psoriasis, allowing subsequent treatment of genital or flexural psoriasis with those agents as well.</p><p><br></p><p><em>Summary for assessment</em></p><p>1.29.<span style=\"font-size: 7pt;\">\u00a0\u00a0\u00a0</span><span style=\"color: black;\">The Advisory Committee considered that the table below summarises its interpretation of the </span>most<span style=\"color: black;\"> appropriate PICO (population, intervention, comparator, outcomes) information for adalimumab if it were to be funded in New Zealand for flexural or genital psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee\u2019s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><br></p><p><span style=\"color: black;\">\ufeff</span><img src=\"/apptracker/servlet/rtaImage?eid=a0POZ00000CdCVW&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000cvwX\" alt=\"image.png\"></img></p>",
          "Status_History__c": "a13OZ000004Hb0wYAC"
        },
        "change": null
      }
    ],
    "dateString": "Mar 2023",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/\" rel=\"nofollow\">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>\r\n<p>&nbsp;</p>\r\n<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>\r\n<ul>\r\n<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>\r\n<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>\r\n<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>\r\n</ul>\r\n<p>&nbsp;</p>\r\n<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",
    "position": 2,
    "name": "Under Assessment",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2023",
          "fs": "Sep 2023",
          "change": null
        },
        "Event_Description": {
          "s": "Working to compare options",
          "fs": "Working to compare options",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVU2A3"
          },
          "Id": "a0POZ00000CdCVU2A3",
          "Event_Date__c": "2023-09-06",
          "Event_Description__c": "Working to compare options",
          "Stage__c": "Under Assessment",
          "Formatted_Date__c": "Sep 2023",
          "Status_History__c": "a13OZ000001tJ83YAE"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2023",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac\u2019s decision-making process.</p>\r\n<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>\r\n<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>\r\n<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",
    "position": 3,
    "name": "Options Compared",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2023",
          "fs": "Sep 2023",
          "change": null
        },
        "Event_Description": {
          "s": "The relative ranking of the pharmaceutical application has been completed.",
          "fs": "The relative ranking of the pharmaceutical application has been completed.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVV2A3"
          },
          "Id": "a0POZ00000CdCVV2A3",
          "Event_Date__c": "2023-09-08",
          "Event_Description__c": "The relative ranking of the pharmaceutical application has been completed.",
          "Stage__c": "Options Compared",
          "Formatted_Date__c": "Sep 2023",
          "Status_History__c": "a13OZ000001vnvTYAQ"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2023",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>\r\n<p><a class=\"external-link\" href=\"https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/\" rel=\"nofollow\">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",
    "position": 4,
    "name": "Under Consultation",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": "<p>Link to Consultation Document - <a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\" style=\"font-family: Arial, sans-serif; font-size: 11pt;\">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a></p>",
          "fs": "<p>Link to Consultation Document - <a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\" style=\"font-family: Arial, sans-serif; font-size: 11pt;\">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a></p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jul 2024",
          "fs": "Jul 2024",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is active.",
          "fs": "Public consultation for this application is active.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVX2A3"
          },
          "Id": "a0POZ00000CdCVX2A3",
          "Event_Date__c": "2024-07-10",
          "Event_Description__c": "Public consultation for this application is active.",
          "Stage__c": "Under Consultation",
          "Summary__c": "<p>Link to Consultation Document - <a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\" style=\"font-family: Arial, sans-serif; font-size: 11pt;\">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/proposal-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab</a></p>",
          "Formatted_Date__c": "Jul 2024",
          "Status_History__c": "a13OZ00000C1DUCYA3"
        },
        "change": null
      }
    ],
    "dateString": "Jul 2024",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",
    "position": 5,
    "name": "Reviewing Consultation Feedback",
    "last": false,
    "events": [
      {
        "Summary": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Jul 2024",
          "fs": "Jul 2024",
          "change": null
        },
        "Event_Description": {
          "s": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "fs": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVY2A3"
          },
          "Id": "a0POZ00000CdCVY2A3",
          "Event_Date__c": "2024-07-30",
          "Event_Description__c": "Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.",
          "Stage__c": "Reviewing Consultation Feedback",
          "Formatted_Date__c": "Jul 2024",
          "Status_History__c": "a13OZ00000CizLqYAJ"
        },
        "change": null
      }
    ],
    "dateString": "Jul 2024",
    "collapsed": false,
    "checked": true
  },
  {
    "text": "<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>\r\n<p>We consider and assess all funding decisions using the&nbsp;<a class=\"external-link\" href=\"https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc\" rel=\"nofollow\">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>\r\n<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>\r\n<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>\r\n<p>&nbsp;</p>",
    "position": 6,
    "name": "Decision",
    "last": true,
    "events": [
      {
        "Summary": {
          "s": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\">Decision notification</a></p>",
          "fs": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\">Decision notification</a></p>",
          "change": null
        },
        "Published_Recommendation": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Discussion": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Published_Application": {
          "s": null,
          "fs": null,
          "change": null
        },
        "PTAC_Comments": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Outcome": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Links": {
          "s": null,
          "fs": null,
          "change": null
        },
        "Formatted_Date": {
          "s": "Sep 2024",
          "fs": "Sep 2024",
          "change": null
        },
        "Event_Description": {
          "s": "The funding application has been approved.",
          "fs": "The funding application has been approved.",
          "change": null
        },
        "e": {
          "attributes": {
            "type": "Application_Event__c",
            "url": "/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000CdCVZ2A3"
          },
          "Id": "a0POZ00000CdCVZ2A3",
          "Event_Date__c": "2024-09-17",
          "Event_Description__c": "The funding application has been approved.",
          "Stage__c": "Decision",
          "Summary__c": "<p><a href=\"https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-to-widen-access-to-aripiprazole-long-acting-injection-ferric-carboxymaltose-methylnaltrexone-bromide-adalimumab-etanercept-secukinumab-and-infliximab\" target=\"_blank\">Decision notification</a></p>",
          "Formatted_Date__c": "Sep 2024",
          "Status_History__c": "a13OZ00000EJwUrYAL"
        },
        "change": null
      }
    ],
    "dateString": "Sep 2024",
    "collapsed": false,
    "checked": true
  }
]